United Therapeutics Corporation
UTHR Healthcare Drug Manufacturers Specialty & Generic
United Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 10.6% from fiscal 2024. In the quarter to June 2026, revenue fell 1.92%, EPS grew 14.0% and free cash flow grew 58.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow UTHR
United Therapeutics Corporation (UTHR) EV/Sales
As of 16 October 2026, United Therapeutics Corporation (UTHR) trades at a EV/Sales of 6.5×. Over the past ten years it has ranged from 1.7× (July 2019) to 7.6× (May 2026); the current reading is higher than 97% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.7× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 6.0× | 31.07% |
| FY2024 | 4.5× | 26.78% |
| FY2023 | 3.6× | (34.79%) |
| FY2022 | 5.5× | 5.07% |
| FY2021 | 5.2× | 31.04% |
| FY2020 | 4.0× | 79.59% |
| FY2019 | 2.2× | (5.27%) |
| FY2018 | 2.3× | (35.28%) |
| FY2017 | 3.6× | 10.32% |
| FY2016 | 3.3× | (23.26%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 6.6× | (13.03%) |
| Mar 2026 | 7.6× | 26.75% |
| Dec 2025 | 6.0× | 17.29% |
| Sep 2025 | 5.1× | 53.14% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VTRS Viatris Inc. compare | 2.3× |
| RDY Dr. Reddy's Laboratories Ltd compare | 2.9× |
| TAK Takeda Pharmaceutical Co. compare | 3.0× |
| ELAN Elanco Animal Health Incorporated compare | 3.0× |
| HLN Haleon PLC Sponsored ADR compare | 3.1× |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 3.5× |
| NBIX Neurocrine Biosciences, Inc. compare | 4.1× |
| ZTS Zoetis Inc. compare | 4.4× |
| UTHR United Therapeutics Corporation | 6.5× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)